Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Completed
1,149 enrolled
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Phase 3 Completed
120 enrolled 14 charts
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
Completed
1,149 enrolled
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Completed
4,626 enrolled
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
Completed
361 enrolled
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Phase 2 Completed
55 enrolled 11 charts
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Phase 1/2 Completed
28 enrolled 10 charts
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
Completed
16 enrolled
FLORENCE
Phase 3 Completed
346 enrolled 16 charts
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Phase 2 Completed
82 enrolled 6 charts
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
Phase 1/2 Completed
18 enrolled
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Phase 3 Completed
280 enrolled 10 charts
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Phase 4 Completed
94 enrolled
Fasturtec TLS Treatment / Prophylysis
Phase 4 Completed
45 enrolled